ArticleG3 (Bethesda, Md.)2025
Efficient iterative CRISPR/Cas9 editing using sid-1 co-conversion and feeding RNAi in Caenorhabditis elegans.
Article in G3 (Bethesda, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We present a sid-1 loss-of-function and restoration-of-function CRISPR/Cas9 co-conversion protocol in Caenorhabditis elegans. Introducing CRISPR reagents that induce sid-1 loss-of-function can produce survivors on lethal RNAi foods while reagents that induce sid-1 restoration-of-function can be screened for restoration of visible RNAi phenotypes. Both methods efficiently reduce the pool of candidates from hundreds or thousands of F1 progeny to tens with minimal experimenter effort. Furthermore, our optimized sid-1 CRISPR design allows a high ratio of CRISPR reagents targeting the gene of interest, maximizing successful co-conversion events. The interconvertibility of the sid-1 locus readily enables this strategy to be leveraged to iteratively create complex strains with multiple gene edits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.